3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Neoplasms by Site
2
Neoplasms
2
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Thoracic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Sarcoma
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Recurrence
1
Pathologic Complete Response
1
Neoplasm Metastasis
1
Lymphoma
1
Lung Diseases
1
Lethal Congenital Contracture Syndrome 2
1
Hemangiosarcoma
1
Head and Neck Neoplasms
1
Fibromatosis, Gingival, 2
1
Carcinoma, Squamous Cell
1
Bronchial Neoplasms
1
Interventions
Carboplatin
19
Pemetrexed
10
Paclitaxel
7
pembrolizumab
5
Nivolumab
5
Cisplatin
5
Gemcitabine
4
osimertinib
3
entinostat
3
camrelizumab
3
atezolizumab
3
Erlotinib Hydrochloride
3
zipalertinib
2
selpercatinib
2
pralsetinib
2
durvalumab
2
apatinib
2
Vinorelbine
2
Surveys and Questionnaires
2
One-Lung Ventilation
2
Ipilimumab
2
Docetaxel
2
Bevacizumab
2
130-nm albumin-bound paclitaxel
2
zimberelimab
1
toripalimab
1
spartalizumab
1
sotorasib
1
sitravatinib
1
sintilimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Lung Diseases
×
patritumab
×
Clear all
NCT02134015
2018-01-23
HER3-Lung
Daiichi Sankyo
Phase 3
Terminated
145 enrolled
20 charts